Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Current Deferred Revenue for 7 consecutive years, with $22.9 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 68.86% to $22.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.9 million through Dec 2025, up 68.86% year-over-year, with the annual reading at $22.9 million for FY2025, 68.86% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $22.9 million at Kymera Therapeutics, down from $23.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $116.2 million in Q3 2021, with the low at $11.5 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $49.1 million, with a median of $45.1 million recorded in 2023.
  • Peak annual rise in Current Deferred Revenue hit 107.7% in 2025, while the deepest fall reached 75.26% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $61.7 million in 2021, then plummeted by 42.89% to $35.3 million in 2022, then soared by 54.99% to $54.7 million in 2023, then tumbled by 75.16% to $13.6 million in 2024, then soared by 68.86% to $22.9 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $22.9 million, $23.3 million, and $40.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.